More Companies Pull Antacid Products in Midst of NDMA Inquiry

As the FDA’s investigation into NDMA contamination in antacid meds continues, Mylan and New Jersey drugmaker Appco Pharm have pulled more products from pharmacy shelves.

Mylan recalled three lots of its nizatidine capsules after trace amounts of the potential carcinogen turned up in product from Indian API manufacturer Solara Active Pharma Sciences.

Appco Pharma also initiated a recall, pulling all consumer-level quantities and lots of its ranitidine hydrochloride 150 and 300 mg capsules from stores.